Factors impacting the efficacy of venlafaxine extended release 75–225 mg/day in patients with major depressive disorder: exploratory post hoc subgroup analyses of a randomized, double-blind, placebo-controlled study in Japan

Yoshinori Watanabe1 Himorogi Psychiatric Institute, Tokyo, Japan

Yuko Asami2 Medical Affairs, Pfizer Essential Health, Pfizer Japan Inc., Tokyo, JapanCorrespondence[email protected]

Yoko Hirano2 Medical Affairs, Pfizer Essential Health, Pfizer Japan Inc., Tokyo, Japan

Kazuhiko Kuribayashi3 Clinical Statistics, Pfizer Japan Inc., Tokyo, Japan

Rio Itamura4 Clinical Research, Pfizer Japan Inc., Tokyo, Japan

Takayuki Imaeda4 Clinical Research, Pfizer Japan Inc., Tokyo, Japan

Citations (3)

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Yong-liang Zhu, Shuang-long Li, Ke-li Chen, Kun-peng Ma, De-qian Wu & Xiang-jun Qiu. (2019) Effect Of Chinese Herb Danzhi Xiaoyao Pills On Pharmacokinetics Of Venlafaxine In Beagles. Drug Design, Development and Therapy 13, pages 3343-3355.
Read now

Articles from other publishers (2)

Heejin Kam & Hotcherl Jeong. (2020) Pharmacogenomic Biomarkers and Their Applications in Psychiatry. Genes 11:12, pages 1445.
Crossref

Dan Liu, Xiao‑Ya Hu, Hai‑Jian Xia, Li‑Jia Wang, Ping Shi, Xiang‑Pan Chen & Qi‑Xin Zhou. (2019) Antidepressant effect of venlafaxine in chronic unpredictable stress: Evidence of the involvement of key enzymes responsible for monoamine neurotransmitter synthesis and metabolism. Molecular Medicine Reports.
Crossref

Factors impacting the efficacy of venlafaxine extended release 75–225 mg/day in patients with major depressive disorder: exploratory post hoc subgroup analyses of a randomized, double-blind, placebo-controlled study in Japan

Articles from other publishers (2)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Factors impacting the efficacy of venlafaxine extended release 75–225 mg/day in patients with major depressive disorder: exploratory post hoc subgroup analyses of a randomized, double-blind, placebo-controlled study in Japan

Citations (3)

Read on this site (1)

Articles from other publishers (2)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date